PFA
BIO icon

Pathway Financial Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pathway Financial Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-227
Closed -$65K – 131
2018
Q2 		$65K Hold
227
– – 0.04% 211
2018
Q1 		$57K Hold
227
– – 0.03% 227
2017
Q4 		$54K Buy
+227
New +$55K 0.03% 258

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Pathway Financial Advisors's BIO Position: Q3 2018 in Review

Pathway Financial Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2018, closing a stake of 227 shares — an estimated $65K sold.

Pathway Financial Advisors first reported a position in BIO in Q4 2017 and held it in 3 quarters. The position peaked at $65K in Q2 2018. 343 funds tracked by Wall St. Rank hold BIO as of Q3 2018.

  • Pathway Financial Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2018 after selling out during the quarter.
  • Pathway Financial Advisors sold 227 Bio-Rad Laboratories Class A shares in Q3 2018, an estimated $65K.
  • Pathway Financial Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 3 quarters.
  • Pathway Financial Advisors's Bio-Rad Laboratories Class A position peaked at $65K in Q2 2018.
  • 343 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2018.

Based on Pathway Financial Advisors's 13F filing for Q3 2018, filed 16 Jan 2019.